Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Lanifibranor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 247,643Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inventiva publishes new biomarker analysis in MASH Patients
    Inventiva publishes new biomarker analysis in MASH Patients

    24 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/24/3067894/0/en/Inventiva-announces-the-publication-in-Clinical-Gastroenterology-and-Hepatology-of-its-analysis-of-new-biomarker-signatures-predictive-of-histological-response-in-patients-with-MAS.html

    GLOBENEWSWIRE
    24 Apr 2025
    Share Share
    Inventiva completes enrollment in Phase 3 trial of lanifibranor
    Inventiva completes enrollment in Phase 3 trial of lanifibranor

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053830/0/en/Inventiva-announces-completion-of-enrollment-in-the-Phase-3-NATiV3-clinical-trial-of-lanifibranor-in-patients-with-MASH-and-advanced-fibrosis.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Inventiva Preclinical Study Lanifibranor Improves Portal Hypertension
    Inventiva Preclinical Study Lanifibranor Improves Portal Hypertension

    26 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/26/3033295/0/en/Inventiva-announces-the-publication-in-Biomedicine-Pharmacotherapy-of-the-results-from-a-preclinical-study-showing-improvement-of-portal-hypertension-with-lanifibranor-treatment.html

    GLOBENEWSWIRE
    26 Feb 2025
    Share Share
    Inventiva, Hepalys Dose First Participant In Japan Ph 1 Lanifibranor Trial
    Inventiva, Hepalys Dose First Participant In Japan Ph 1 Lanifibranor Trial

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/20/3030046/0/en/Inventiva-and-Hepalys-Pharma-Inc-announce-the-initiation-of-the-clinical-development-program-of-lanifibranor-in-Japan-with-the-dosing-of-the-first-participant-in-Phase-1-trial.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    Inventiva Publishes Lanifibranor Trial Results In T2D, MASLD
    Inventiva Publishes Lanifibranor Trial Results In T2D, MASLD

    29 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/29/3017552/0/en/Inventiva-announces-the-publication-of-the-results-from-the-investigator-initiated-proof-of-concept-clinical-trial-evaluating-lanifibranor-in-patients-with-T2D-and-MASLD-in-the-Jou.html

    GLOBENEWSWIRE
    29 Jan 2025
    Share Share
    Legend Study On Lanifibranor In MASH At EASL SLD Summit 2025
    Legend Study On Lanifibranor In MASH At EASL SLD Summit 2025

    22 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/22/3013844/0/en/Results-of-LEGEND-evaluating-lanifibranor-in-combination-with-empagliflozin-in-MASH-selected-for-oral-presentation-at-the-upcoming-EASL-SLD-Summit-2025.html

    GLOBENEWSWIRE
    22 Jan 2025
    Share Share